RIVAROXABAN (Xarelto) prior authorization at Blue Cross NC
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Blue Cross NC requires Factor Xa Inhibitor prior-authorization documentation for RIVAROXABAN (Xarelto): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Blue Cross NC reviews RIVAROXABAN (Xarelto) prior authorizations against its medical policy for Factor Xa Inhibitor. Blue Cross NC-specific context: BCBS licensee for North Carolina (~4.3M members). Prime Therapeutics PBM. NC DOI oversight. Blue Premier is the high-profile value-based care program. Recently divested some Medicaid business; Healthy Blue (joint venture with Elevance) handles NC Medicaid.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Factor Xa Inhibitor
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Blue Cross NC's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Step therapy via Prime Therapeutics
- Blue Premier value-based arrangement disputes
- Out-of-network reductions
- Specialty drug PA
RIVAROXABAN (Xarelto)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring warfarin first
- Non-formulary
Brand: Xarelto.
Manufacturer patient-assistance program: Xarelto Cares — relevant when a Blue Cross NC denial sticks and the patient needs bridge access while appealing.
How Blue Cross NC approaches Direct oral anticoagulants (DOACs) PAs
For RIVAROXABAN (XARELTO), check whether the current Blue Cross NC Direct oral anticoagulants (DOACs) policy cites step therapy via prime therapeutics. Pharmacy-benefit review for RIVAROXABAN (XARELTO) at Blue Cross NC is routed through Prime Therapeutics. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Blue Cross NC; if denied, use the filing date and route printed on that denial notice. Blue Cross NC's warfarin-step-first policy is defensible only when the patient lacks documented intolerance, labile INR, drug-interaction risk, or non-valvular AF with stroke risk — citing AHA/ACC/HRS 2023 typically overturns. Blue Cross NC is domiciled in NC, so unresolved appeals escalate to the NC insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.bluecrossnc.com/providers) with the same packet plus an applicable, current clinical source supporting RIVAROXABAN (Xarelto)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Blue Cross NC denial on DenialHelp.
Contact Blue Cross NC
- Provider portal: https://www.bluecrossnc.com/providers
Frequently asked questions
What documentation does Blue Cross NC need for RIVAROXABAN (Xarelto) prior auth?
Blue Cross NC's typical PA packet for RIVAROXABAN (Xarelto): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Factor Xa Inhibitor, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Blue Cross NC?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for RIVAROXABAN (Xarelto) at Blue Cross NC?
Preparation scenarios to check against the current notice and policy include: Step therapy via Prime Therapeutics; Blue Premier value-based arrangement disputes; Out-of-network reductions. These are not measured frequency claims. For RIVAROXABAN (Xarelto), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Will Blue Cross NC accept a contraindication to warfarin instead of a warfarin trial for RIVAROXABAN (XARELTO)?
Yes — Blue Cross NC accepts documented warfarin contraindication or intolerance in place of a warfarin trial. Acceptable contraindications include labile INR (TTR <60% on prior warfarin), high bleeding risk (HAS-BLED ≥3), drug-interaction burden, valvular AF (which actually mandates warfarin, not contraindicates), or patient inability to comply with INR monitoring. Cite AHA/ACC/HRS 2023 AF Guideline language for the DOAC-first rationale in non-valvular AF. Pharmacy-benefit handling is routed through Prime Therapeutics. External-review escalation for Blue Cross NC fully-insured policies sits with the NC insurance department.
How do I prep for a peer-to-peer with Blue Cross NC on RIVAROXABAN (Xarelto)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the RIVAROXABAN (Xarelto) PA packet
Open ApprovalHelp — generate a RIVAROXABAN (Xarelto) prior-auth packet tailored to Blue Cross NC's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com